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The rapid increase in the number of diabetic patients globally and exploration of alternate insulin delivery methods
such as inhalation or oral route that rely on higher doses, is bound to escalate the demand for recombinant insulin
in near future. Current manufacturing technologies would be unable to meet the growing demand of affordable
insulin due to limitation in production capacity and high production cost. Manufacturing of therapeutic recombinant
proteins require an appropriate host organism with efficient machinery for posttranslational modifications and protein
refolding. Recombinant human insulin has been produced predominantly using E. coli and Saccharomyces cerevisiae for
therapeutic use in human. We would focus in this review, on various approaches that can be exploited to increase the
production of a biologically active insulin and its analogues in E. coli and yeast. Transgenic plants are also very attractive
expression system, which can be exploited to produce insulin in large quantities for therapeutic use in human.
Plant-based expression system hold tremendous potential for high-capacity production of insulin in very cost-effective
manner. Very high level of expression of biologically active proinsulin in seeds or leaves with long-term stability, offers a
low-cost technology for both injectable as well as oral delivery of proinsulin.
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The pioneering work of Stanley Cohen and Herbert
Boyer, who invented the technique of DNA cloning, sig-
naled the birth of genetic engineering, which allowed
genes to transfer among different biological species with
ease [1]. Their discovery led to the development of sev-
eral recombinant proteins with therapeutic applications
such as insulin and growth hormone. Genes encoding
human insulin and growth hormone were cloned and
expressed in E. coli in 1978 and 1979 respectively. The
first licensed drug produced using recombinant DNA
technology was human insulin, which was developed by
Genentech and licensed as well as marketed by Eli Lilly
in 1982.
There are more than 300 biopharmaceutical products
including therapeutic proteins and antibodies in the
market with sales exceeding USD100 billion [2,3]. Thera-
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unless otherwise stated.market share (>USD18 billion) followed by the hor-
mones (>USD11 billion) and growth factors (>USD10
billion) [4]. Biopharmaceuticals approved by the US
Food and Drug Administration (FDA) and European
Medicines Agency (EMA) from 2004 to 2013 are largely
derived from mammalian cell (56%); E. Coli (24%); S.
Cerevisiae (13%); Transgenic animals & plants (3%) and
insect cells (4%) as shown in Figure 1 [5-13]. At present,
insulin is being produced predominantly in E. coli and
Saccharomyces cerevisiae for treatment of diabetic
patients.
Since the early 1920s, diabetic patients were treated
with insulin, which was purified from bovine or porcine
pancreas. The development in the field of genetic engin-
eering allowed the production of insulin in E. coli and
yeast, which have been approved for therapeutic applica-
tions in human by FDA [14,15].
Nowadays, recombinant human insulin is mainly
produced either in E. coli or Saccharomyces cerevisiae.
Using E. coli expression system, the insulin precursors (IP)
are produced as inclusion bodies and fully functional
polypeptides are obtained finally by solubilization and
refolding procedures [16]. Yeast based expression system
yield soluble IP which is secreted into the culturel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Percentage of biopharmaceuticals produced in different expression systems [5-13].
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preferred and predominant yeast for large scale commer-
cial production of insulin, however several other alternate
yeast strains have been explored for insulin production
[20-24]. Besides, E.coli and yeast, mammalian cells, trans-
genic animals and plant expression systems are also
employed as a host for large-scale production of recombin-
ant insulin [25-28].
The incidence of diabetes is increasing at an alarming
rate and it has been speculated that the number of dia-
betic patients worldwide would increase to approxi-
mately 300 million by the year 2025 [29]. Consequently,
the requirement for insulin will increase manifold
(approximately more than 16000 kg/ year) and the
productivity of current insulin expression system would
not be sufficient to meet the future market demands.
Efficient expression systems for insulin production are
also needed and novel route for insulin administration
such as oral or inhalation are to be developed.
Several recombinant protein based drugs, produced
by various expression systems are approved by FDA.
Among prokaryotes, Escherichia coli has always been
preferred for production of recombinant proteins as it
offered several advantages including high growth rate,
simple media requirement, easy to handle, high yield
and very cost effective. However, there are some disad-
vantages using E. coli expression system, such as loss
of plasmid and antibiotic property, unsolicited in-
ducers for gene expression, intracellular accumulation
of heterologous proteins as inclusion bodies, improper
protein refolding, lack of post- translational modifica-
tions (including unable to form disulphide bonds),
protein-mediated metabolic burden and stress, endotoxin
contamination, poor secretion, proteolytic digestion and
complexity in downstream process [30-32].Among yeast strains, Saccharomyces cerevisiae, Hanse-
nulla polymorpha and Pichia pastoris are very com-
monly used for production of recombinant proteins
[21,24,33-35]. Like E. coli, they grow rapidly and are very
easy to handle and amenable to various genetic manipu-
lations. Recombinant proteins produced in yeast are
properly folded and glycosylated to a certain extent similar
to the one expressed in mammalian cells. Various human
therapeutic proteins, including therapeutic monoclonal
antibodies are being produced in mammalian cell lines
such as Chinese hamster ovary (CHO) and Baby hamster
kidney (BHK) cells. Recombinant proteins expressed in
mammalian cells are properly folded, glycosylated and
generally yield a functionally active protein [36]. However,
the production cost of biopharmaceuticals using mamma-
lian expression system is very high due to expensive cul-
ture media. However, when we look at the number of
approved biopharmaceuticals by United States and/or the
European Union for 2013 recorded above average as com-
pared to past five years. The mean rate of approval is 13 as
shown in the Figure 2 [5-13]. Remarkably, the number is
same for both the years 2009 and 2013.
Structure and function of insulin
The human insulin is comprised of 51 amino acids and
has a molecular weight of 5808 Da. It is produced by
beta cells of the pancreas and plays a key role in regulat-
ing carbohydrate and fat metabolism in the body. Insulin
is synthesized as a single polypeptide known as preproin-
sulin in pancreatic beta cells. Preproinsulin harbours a
24-residue signal peptide, which directs the nascent poly-
peptide to the endoplasmic reticulum. The signal peptide
is cleaved as the polypeptide is translocated into the
human of the endoplasmic reticulum resulting in the for-
mation of proinsulin. In the Endoplasmic reticulum, the
Figure 2 Approval numbers of biopharmaceuticals in United States and/or European Union over the past six years with a trend line
showing the mean approval rate [5-13].
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mation of 3 disulphide bonds. Folded proinsulin is then
transported to the trans-Golgi network, where it is
converted into active insulin by cellular endopeptidases
called as prohormone convertases (PC1 and PC2) and
exoprotease carboxypeptidase E. The endopeptidases
cleaves at two positions, resulting in the release of a frag-
ment termed as C-peptide. The mature insulin, thus
formed consists of an A-chain with 21 aminoacids and a
B-chain containing 30 aminoacids and both polypeptides
linked together by two disulphide bonds. Besides, the
A-chain has an intrachain disulphide bond [37,38].
E. coli expression system for production of insulin
E. coli is a preferred microorganism for large-scale pro-
duction of recombinant proteins. However, several dis-
advantages limit its use for production of recombinant
biopharmaceuticals. Various post-translational modifica-
tions (PTMs) such as glycosylation, phosphorylation,
proteolytic processing and formations of disulfide bonds
which are very crucial for biological activity, do not
occur in E. coli [39,40]. N-linked glycosylation is the
most common posttranslational modification of proteins
in eukaryotes. It has been discovered that the bacterium
Campylobacter jejuni possess the capability to glycosy-
late the proteins and it was also shown that a function-
ally active N-glycosylation pathway could be transferred
to E. coli [41]. Although the structure of bacterial N-glycan
is different from that observed in eukaryotes, engineering
of Campylobacter N-linked glycosylation pathway into
E. coli, provides an opportunity to express heterologous
proteins in glycosylated form in E. coli. Expression of Pglb
oligosaccharyltransferase or (OTase) from C. jejuni in
E. coli showed a significant increase in glycopepetide
yield [42,43]. Recently efforts has been made to produceglycosylated proteins with substrates other than native and
non-native to E. coli and C.jejuni [44-48].
The codon usage of the heterologous protein also
plays a major role in determining the expression level of
recombinant protein. If the codon usage of heterologous
protein differs significantly from the average codon
usage of the E. coli host, it could result in very low ex-
pression. Usually, the frequency of the codon usage
reflects the abundance of their corresponding tRNA.
Therefore, significant differences in codon usage could
result in premature termination of translation, misincor-
poration of aminoacids and inhibition of protein synthe-
sis [49]. Expression of heterologous proteins in E. coli
can be improved by replacing codons that are rarely
found in highly expressed E. coli genes with more favor-
able major codons. Similarly, co-expression of the genes
encoding for a number of the tRNA for rare codon, may
enhance the expression of heterologous proteins in
E. coli. There are some commercial E. coli strains avail-
able that encodes for tRNA for rare codons such as
BL21 (DE3) CodonPlus-RIL, BL21 (DE3) CodonPlus-
RP (Stratagene, USA) and Rosetta (DE3). BL21 (DE3)
CodonPlus-RIL harbors tRNA genes for rare codons
like AGG, AGA (arginine), AUA (isoleucine) and CUA
(leucine). Similarly, Rosetta (DE3) strain harbors tRNA
genes for rare codons like AGG, AGA (arginine), CGG
(arginine), AUA (isoleucine), CUA (leucine), CCC (proline)
and GGA (glycine). These rare codons have been asso-
ciated with low expression of proteins in E. coli, hence
application of these genetically engineered E. coli host
strains may improve the expression level of heterol-
ogous proteins and thus might result in higher yield of
desired protein [50-52]. The use of protease-deficient
E. coli strains, which carry mutations that eliminate
the production of proteases may also improve the yield
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radation. E. coli strain BL-21, is deficient in two pro-
teases encoded by the lon (cytoplasmic) and ompT
(periplasmic) genes. Rather than the external parameters,
targeted methods such as modifications in protease or se-
cretion pathways can provide the insight into biology of
recombinant proteins [53]. In E. coli, complex and large
therapeutic proteins can be secreted in periplasm as it
provides an oxidizing environment and help in forming
disulphide bonds, which facilitate the proper folding
of recombinant proteins and likely to yield reliable
N- terminus of expressed protein [54]. Periplasm has ad-
vantages over cytoplasm in less protein concentration
and proteolytic activity, improve the production titer
[55], and enhance the solubility of recombinant protein.
Altogether, with these advanced modifications and devel-
opments ease the process of target protein production
thus accelerating the drug development [56].
Heterologous proteins generally accumulate in E. coli
as inclusion bodies, which comprise of insoluble mis-
folded aggregates of proteins. Use of molecular chaper-
ones may increase the protein solubility and assist in
proper folding of recombinant protein. Some of the
chaperones prevent aggregation of protein and some as-
sist in refolding and solubilization of misfolded proteins.
The most important chaperones in E. coli are GroEL,
GroES, DnaK, DnaJ, GrpE and Trigger factor. These
chaperones may be used singly, or in combination to en-
hance the protein solubility in E. coli [57,58].
Recombinant human insulin was first produced in
E. coli by Genentech in 1978, using a approach that re-
quired the expression of chemically synthesized cDNA
encoding for the insulin A and B chains separately in
E. coli [59]. After expressing independently, the two
chains are purified and co-incubated under optimum re-
action conditions that promoted the generation of intact
and bioactive insulin by disulphide bond formation. The
first commercial recombinant insulin was developed for
therapeutic use in human by this two-chain combination
procedure [60]. Another approach involves the expres-
sion of a single chemically synthesized cDNA encoding
for human proinsulin in E. coli followed by purification
and subsequent excision of C-peptide by proteolytic di-
gestion. This approach was more efficient and conveni-
ent for large scale production of therapeutic insulin as
compared to the two chain combination approach and
has been used commercially since 1986 [60]. Eli Lilly
followed this technology to produce Humulin, the first
recombinant insulin approved in 1982, for the treatment
of diabetic patients. These first generation recombinant
insulins have an amino acid sequence identical to native
human insulin and are preferred over animal derived in-
sulin products [14]. However, advancement in the field
of genetic engineering and development of technologyto chemically synthesize genes with altered nucleotide
sequence, facilitated the development of insulin ana-
logues with altered amino acid sequence. It had been ob-
served that native insulin in commercial preparations
usually exist in oligomeric form, as zinc-containing hex-
amer due to very high concentration, but in blood,
biologically active insulin is in monomeric form [61].
Hence, this oligomeric complex should dissociate so that
insulin can be absorbed from the site of injection into
the blood. Due to this, subcutaneously injected recom-
binant insulin usually have a slow onset with peak
plasma concentration after 2 hours of injection and longer
duration of action that last for 6–8 hours [62]. Hence, in
order to develop a fast- acting insulin analogue, it was re-
quired to modify the amino acids residues whose side
chains are involved in dimer or oligomer formation. It has
been shown that amino acids residues in insulin B-chain
particularly B8, 9,12, 13, 16 and 23-28 play critical role in
oligomerization [63,64]. Lispro, developed by Eli Lilly, was
the first fast acting insulin analogue to obtain regulatory
approval in 1996, for therapeutic use [60]. Insulin Lispro is
engineered in such a way that it has similar amino
acid sequence as the native insulin but has an inver-
sion of proline-lysine sequence at position 28 and 29
of the B-chain, which resulted in reduced hydrophobic
interactions and thus prevented dimer formations. For
commercial production of insulin Lispro, a synthetic
cDNA encoding for Lys B28- Pro B29 human proinsulin
was expressed in E. coli and insulin Lispro was excised
proteolytically from the proinsulin by treating with
trypsin and carboxypeptidase. Another rapid-acting insu-
lin analogue, produced in E. coli is Glulisine (Apidra)
which was developed by Aventis Pharmaceuticals and
approved by US regulatory authorities in 2004. Insulin
Glulisine have been generated by replacing B3 aspara-
gine by a lysine and B29 lysine replaced by glutamic
acid [14].
To avoid multiple injection, long-acting insulin ana-
logues with prolonged duration of actions have also
generated. Insulin Glargine is one of such long-acting
insulin analogues, which was developed by Aventis
Pharmaceuticals and approved by regulatory authorities
of USA and EU in 2000. Insulin Glargine was generated
by replacing the C-terminal asparagine of the A-chain
with a glycine residue and the C-terminal of the B- chain
was modified by adding two arginine residues. These
modifications resulted in increase of the isoelectric
point (pI) from 5.4 to neutral values. Glargine was pro-
duced as proinsulin and expressed in E. coli and was fi-
nally formulated at pH 4 in soluble form. However, after
subcutaneous administration, it precipitated due to neu-
tral pH in the subcutaneous tissue. Resolubilization of
insulin occur slowly, resulting in longer duration for its
release in the blood [14].
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Yeast is a preferred host for expression of various heter-
ologous proteins that require post-translational modifi-
cations for its biological activity. Yeast cell has the
ability to carry out numerous post-translational modifi-
cations such as phosphorylation, O-linked glycosylation,
N-linked glycosylation, acetylation and acylation. Re-
combinant proteins are expressed in soluble form in
yeast and properly folded in functionally active form.
Production of biopharmaceuticals using yeast expression
system is also very cost effective and is amenable to scale
up using large bioreactors. However, one major concern
for producing therapeutic glycoprotein for human appli-
cation is that yeast N-glycosylation is of the high-
mannose type, which confers a short half-life in vivo and
hyper–immunogenicity and thus render the therapeutic
glycoprotein less effective. Various attempts have been
made to humanize yeast N-glycosylation pathways in
order to produce therapeutic glycoproteins with human-
ized N-glycosylation structure [65].
The therapeutic proteins produced in yeast are specif-
ically from Saccharomyces cerevisiae and include hor-
mones (insulin, insulin analogues, non-glycosylated
human growth hormone somatotropin, glucagon), vac-
cines (hepatitis B virus surface antigen), uprate oxidase
from Aspergillus flavus, granulocyte-macrophage colony
stimulating factor, albumin, hirudin of Hirudo medi-
cinalis and human platelets derived growth factor [34].
Like E. coli, yeast derived recombinant biopharmaceuti-
cals majorly intended as therapeutics for infectious dis-
eases or endocrine, metabolic disorders. Alternate yeast
strains, besides S. cerevisiae, are being explored for large-
scale production of biopharmaceuticals. Specifically,
Pichia pastoris has the ability to attain high cell dens-
ities by its robust methanol-inducible alcohol oxidase 1
(AOX1) promoter and simple developmental approaches
contribute to high quality and quantity of recombinant
proteins production. In comparison to Saccharomyces
cerevisiae, Pichia pastoris provides a major advantage
in the glycosylation of secreted proteins because it
does not hyperglycosylate the heterologous proteins.
Both yeast strains have a majority of N-linked glyco-
sylation of the high-mannose type, but the length of
the oligosaccharides chain added to proteins in Pichia
(around 8–14 mannose residues per side chain) is much
shorter than those expressed in Saccharomyces cerevisiae
(approximately 50–150 mannose residues per side chain),
suggesting that glycoproteins produced in Pichia pastoris
may be more suitable for therapeutic use in humans
[66,67]. Moreover, very high level of expression of heterol-
ogous proteins can be attained in Pichia pastoris, that
might constitute about 30% of total cellular protein which
is very high as compared to S. cerevisiae [68,69]. There-
fore, Pichia pastoris can be an attractive alternate forlarge-scale production of recombinant insulin and insulin
analogues. Comparing the different insulin production
systems where the bacterial expression systems show
higher average specific productivity and maximum bio-
mass concentrations are higher in yeast, the overall pro-
duction space-time yield remains similar as shown in
Table 1 [70].
Saccharomyces cerevisiae has been extensively used to
produce recombinant human insulin since early 1980s
[17,18] and a large proportion of recombinant commer-
cial insulins are produced by this yeast expression sys-
tem [19,74]. For efficient expression and secretion of
recombinant proinsulin in yeast, insulin construct was
engineered to contain the native A-chain and a B-chain
lacking the C-terminal B30 threonine, either directly
fused or linked via a short synthetic C peptide (like
AAK). The cDNA sequence encoding for this construct
was fused with α-factor signal sequence of Saccharomy-
ces cerevisiae for secreted expression of proinsulin which
gave yield upto 80 mg/ml of insulin. The single chain
proinsulin was purified and converted to active insulin
by a trypsin-mediated transpeptidation reaction in pres-
ence of threonine ester [19]. Besides native recombinant
insulin, various insulin analogues are also being produced
in S. cerevisiae. Insulin Aspart is another fast-acting insu-
lin analogue, which was produced in S. cerevisiae, de-
veloped by Novo Nordisk and approved by US FDA in
2001 for therapeutic use in human. Insulin Aspart was
generated by replacing proline residue at position 28
with aspartic acid in the B-chain. This genetic modifi-
cation resulted in an increase in inter-chain charge re-
pulsion, decrease in self-association and thus causing
rapid entry into the blood from the site of subcutaneous
injection [63,75].
Insulin Detemir is another recombinant long-acting
insulin analogue that was commercially produced in
S. cerevisiae, developed by Novo Nordisk and approved
for therapeutic use in human in 2004 by European regu-
latory authorities. Recombinant Detemir have been gen-
erated by removing the threonine residue at the 30
position of the B-chain, and a C14 fatty acid chain cova-
lently attached to the lysine residue at the 29 position of
the B-chain. These genetic alterations resulted in the
binding of insulin to albumin in plasma, which ensured
the slow and constant release of insulin and thus
prolonging its duration of action up to 24 hours [76-78].
Sacharomyces cerevisiae has been reported for the pro-
duction of more than 40 different recombinant proteins
[79]. A few of which related to diabetes are illustrated in
Table 2, along with different characteristics. Few proteins
secreted extracellularly by Sacharomyces cerevisiae with
α-factor leader sequence being repeatedly used for ad-
equate production of recombinant proteins. Further-
more, a synthetic leader sequence had been developed
Table 1 Comparison of human insulin production systems [70]
Source E. coli E. coli S. cerevisiae P. pastoris
Destination of product Cytoplasm Secreted Secreted Secreted
Biomass cell dry weight (g/l) 80, in bioreactor with
fed-batch culture
1.2, in shake flask with
batch culture
5, in shake flask with
batch culture
59, in bioreactor with
fed-batch culture
Typical spec. growth rate (1/h) 0.08– 0.12 not specified < 0.33 <0.03
Typical spec. production rate (mg/gh) 14.2 3.4 0.21 0.375
Product concentration (g/L) 4.34 0.009 0.075 3.075
Productivity (mg/l h) 1,085 4.01 1.04 17
Reference [71] [72] [19] [73]
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ficient protein secretion in yeast [79,80].
Transgenic plants as host for insulin production
Transgenic plants have been utilized to produce recom-
binant proteins because of their advantage of cost effect-
iveness, high quality protein processing, absence of
human pathogens, ease of production and presence of
eukaryotic machinery for posttranslational modifications.
Initially, the human growth hormone was the recombin-
ant protein product extracted from transgenic tobacco
plant [81]. After that, numerous different products
have developed from plants such as Hepatitis-B-Virus
surface antigen, antibodies, industrial proteins and milk
proteins.
Recombinant human insulin has been successfully
expressed and produced in oilseeds of plant Arabidopsis
thaliana [27]. This technology involved the targeted ex-
pression of insulin in subcellular organelles known as
oilbodies that allowed very high level of expression with
easy recovery of recombinant insulin. Oilbodies are
storage organelles inside the oilseeds, which comprises
of hydrophobic triacylglycerol core encapsulated by
phospholipid membrane and an outer wall of proteins
known as oleosins. Genetically engineered oil seeds have
been generated with recombinant protein specifically
targeted to oilbodies as oleosin fusion [27,82,83]. Then
the oilbodies are easily separated from other seed com-
ponents by liquid-liquid phase separation, which re-
duced the number of chromatography steps required to
obtain purified insulin. It has been observed that insulin
accumulated to high level in transgenic seed (0.13% of







Hormones Insulin Precursor Diabetes Synthetic 80 mg/L
Glucagon Diabetes α-Factor 17.5 mg/Lfrom the oleosin fusion partner and matured with tryp-
sin digestion following oil body purification to yield a
biologically active insulin. This study clearly demon-
strated that expression of insulin as oleosin fusion pro-
tein in plant allow accumulation of large amount of
recombinant insulin within the seed and also provide
simple downstream purification by centrifugation i.e. oil-
body purification. Subsequent maturation to obtain bio-
logically active insulin can be accomplished using standard
enzymatic methods currently used for commercial produc-
tion of insulin from E. coli and yeast. Oilseeds also act as a
natural cellular warehouse, where recombinant insulin can
be stockpiled until required [27].
In another approach, transgenic plants have been gen-
erated, in which, tobacco and lettuce chloroplasts were
transformed with human proinsulin comprised of A, B
and C-chains fused with the cholera toxin B subunit
[28]. It has been observed that, old tobacco leaves accu-
mulated proinsulin upto 47% of total leaf protein and
similarly, old lettuce leaves amassed proinsulin up to
53% of total leaf protein. Proinsulin stored in leaves of
lettuce was found to be very stable as up to 40% of pro-
insulin was detected even in senescent and dried leaves
as shown in Table 3. Proinsulin from tobacco leaves was
extracted with 98% purity and cleaved by Furin protease
to release insulin peptides. Oral delivery of unprocessed
proinsulin encapsulated in plant cell or by injection into
mice revealed lowering of blood glucose levels similar
to commercially available insulins. Based on the yield
(3 mg of proinsulin/gm of leaves), it was estimated
that one acre of tobacco plantation could yield uptoTable 3 CTB cholera toxin B subunit proinsulin expression
in tobacco and lettuce chloroplasts [28]
Type of transgenic plant Tobacco Lettuce
Destination of the product Chloroplast Chloroplast
Percentage of Total leaf protein 47% 53%
Protein yield per gram of leaf tissue 2.92/gm 3.28/gm
Reference [28]
Baeshen et al. Microbial Cell Factories 2014, 13:141 Page 7 of 9
http://www.microbialcellfactories.com/content/13/1/14120 million daily doses of insulin per year [28]. C-peptide
of proinsulin, which is not present in current commer-
cially available insulin and insulin analogues derived from
E. coli and S. cereviciae, would be a great advantage in
long-term treatment of diabetic complications such as
stimulation of nerve and renal functions. Very high level
of expression of biologically active proinsulin in tobacco
and lettuce leaves and long-term stability in dried leaves
offers a reliable low-cost technology for both injectable
as well as oral delivery of proinsulin.
Conclusion
Over the next 20 years, WHO has estimated that insulin
sale would grow from $12 billion to $54 billion globally.
Dietary and lifestyle changes are causing dramatic in-
crease in diabetes incidence all over the world. Both
Type I and Type II diabetic patients use insulin, however
late stage Type II diabetes patients require large doses of
insulin as they develop insulin resistance. The dramatic
increase in the number of diabetic patients globally and
exploration of alternate insulin delivery methods such as
inhalation or oral route is bound to escalate the demand
for recombinant insulin in near future. Current manu-
facturing technologies will not be able to meet the grow-
ing demand of insulin due to limitation in production
capacity and high production cost. Recombinant human
insulin is produced predominantly using E. coli and Sac-
charomyces cerevisiae for therapeutic use in human.
However, there is an upmost need to increase the pro-
duction by several fold of a biologically active insulin and
its analogues from E. coli and yeast using latest novel and
efficient technologies. Another strategy, using a different
expression host other than E. coli and Saccharomyces
cerevisiae could be employed. Plant-based expression sys-
tem hold tremendous potential for high-capacity produc-
tion of insulin in very cost-effective manner. Very high
level of expression of biologically active proinsulin in
seeds or leaves with long-term stability, offers a low-cost
technology for both injectable as well as oral delivery of
proinsulin. Moreover, transgenic seeds can also act as
warehouse where recombinant insulin can be stockpiled
until required.
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